Health tech investing during Trump 2.0
With the presidential inauguration roughly a month away, we checked in with some top health tech investors about what they're predicting. Most don't expect huge changes, though they anticipate some...
View ArticlePfizer projects stability for 2025 amid turbulence in DC
Pfizer is targeting a steady 2025, promising pipeline trims, cost cuts and smaller deals as it works to reassure investors about its path forward. What it's not projecting is much growth. Its revenue...
View ArticleIn surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024
FDA Principal Deputy Commissioner Namandjé Bumpus told FDA staff that she will leave the agency by the end of the year, according to emails reviewed by Endpoints News. Bumpus, the agency's former chief...
View ArticleRegeneron looks to expand label of Eylea HD early next year
The high-dose version of Regeneron's eye treatment Eylea hit its primary endpoint in a late-stage study for macular edema following retinal vein occlusion, a common eye disease where fluids build up in...
View ArticleSandoz agrees to $275M settlement in generic antitrust litigation
Sandoz has agreed to pay $275 million to settle multidistrict generic price-fixing claims brought by a group that includes some insurers and employee benefit plans. The deal doesn’t force Sandoz to ...
View ArticleMajor PBM reforms feature in Congress' year-end spending bill
An end-of-year spending bill will include major reforms to the ways pharmacy benefit managers operate, including significant new restrictions on the fees and rebates that have huge influence over the...
View ArticleJazz Pharmaceuticals CEO and co-founder announces retirement
Jazz Pharmaceuticals CEO Bruce Cozadd is ready to play his outro. On Monday, Cozadd announced plans to retire, nearly 22 years after co-founding Jazz and 15 years after becoming chief executive ...
View ArticleSiteOne Therapeutics, a pain biotech that's partnered with Vertex, nabs $100M
About eight years after its Series B, a small biotech working on non-opioid treatments has raised its Series C to gather clinical proof of concept in acute and chronic pain. And it’s a big round ...
View ArticleAurion’s eye cell therapy improves vision in small study, plots Phase 3 trial
Aurion Biotech said its cell therapy for treating the cornea improved vision at the highest dose, which it plans to further study in a Phase 3 trial beginning later next year. The Seattle-based biotech...
View ArticleExclusive: Insitro finds new ALS drug target in Bristol Myers deal
The AI-focused biotech insitro is advancing a new idea to potentially treat ALS, one of the most intractable and brutal diseases. The South San Francisco-based startup has identified a new drug target...
View ArticleNovo Nordisk partners with Broad Institute spinout Photys after the startup's...
Novo Nordisk is exploring a new class of small molecule drugs that act as matchmakers between two proteins in partnership with a biotech startup called Photys Therapeutics. The companies will work on...
View ArticleNovartis and BioAge partner on longevity, exercise targets
BioAge Labs, which began nearly a decade ago as an anti-aging biotech and then turned to obesity this year, is going back to its roots and teaming up with Novartis to find new drug targets ...
View ArticleRing Therapeutics cuts workforce in latest round of layoffs as CEO departs
Ring Therapeutics, a startup looking to advance a new type of virus to deliver gene therapies, has let go "just under 50%" of its workforce, a spokesperson told Endpoints News Wednesday morning. Ring...
View ArticleMerck’s long-awaited obesity move is an oral GLP-1 from China
Merck is finally making a move in obesity by licensing an oral GLP-1 candidate, though it's happening years after some of its big pharma peers. Like AstraZeneca did a year ago with ...
View ArticleTessera gets up to $50M from the Gates Foundation; Tvardi’s reverse merger
Plus, news about Sensorion, Soleno Therapeutics, Corvus and Hansa Biopharma: Tessera Therapeutics bags up to $50M for sickle cell disease R&D: The investment is part of Tessera’s new agreement with...
View ArticleBiosecure Act influence still felt even as China bill stalls
Last March, I received a flurry of texts and emails from readers. It was one of the strongest reactions I’ve ever gotten to an article. Endpoints News had just published my piece ...
View ArticleNovartis, AbbVie and PhRMA secure 340B court win in West Virginia
Novartis, AbbVie and industry group PhRMA on Tuesday notched a victory over a West Virginia law that would have required the companies to distribute drugs at reduced prices to an unlimited number of...
View ArticleUS drug spending surged to almost $450B in 2023
Popular weight loss and diabetes treatments contributed to a “faster overall growth” in prescription drug spending last year, according to a new report from the Centers for Medicare & Medicaid...
View ArticleDavid Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field
David Epstein has retired three times. And he quickly went to work when he got back in the saddle earlier this fall as CEO and chair of Ottimo Pharma, a preclinical biotech trying to take ...
View Article